APA

Kourlaba G., Rapti V., Alexopoulos A., Relakis J., Koumakis G., Chatzikou M., Maniadakis N. & Georgoulias V. (20160112). Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. : BMC health services research.

Chicago

Kourlaba Georgia, Rapti Vasiliki, Alexopoulos Athanasios, Relakis John, Koumakis Georgios, Chatzikou Magdalini, Maniadakis Nikos and Georgoulias Vassilis. 20160112. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. : BMC health services research.

Harvard

Kourlaba G., Rapti V., Alexopoulos A., Relakis J., Koumakis G., Chatzikou M., Maniadakis N. and Georgoulias V. (20160112). Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. : BMC health services research.

MLA

Kourlaba Georgia, Rapti Vasiliki, Alexopoulos Athanasios, Relakis John, Koumakis Georgios, Chatzikou Magdalini, Maniadakis Nikos and Georgoulias Vassilis. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. : BMC health services research. 20160112.